The biotech firm reported a narrower-than-expected loss and revenue exceeding forecasts despite a 14.5% year-over-year decline.
MaxCyte posted a Q2 GAAP loss per share of $0.08, beating estimates by $0.01. Revenue reached $7.27 million, surpassing expectations by $0.8 million, though down 14.5% from the same period last year.
The company’s full-year 2026 revenue guidance projects $30 million to $32 million, including $25 million in core revenue. Prior-year revenue and consensus estimates were not provided for comparison.
No immediate market reaction was detailed in the release.